United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.51 (+8.17%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Array Biopharma announces Phase 3 Beacon CRC SPA agreement with FDA
Wednesday, 14 Sep 2016 07:30am EDT 

Array Biopharma Inc : Array biopharma announces phase 3 beacon crc spa agreement with fda . Array biopharma announces phase 3 beacon crc spa agreement with fda .Patient enrollment is expected to be completed in 2018.  Full Article

Array Biopharma enters into note purchase agreement
Friday, 2 Sep 2016 05:15pm EDT 

Array Biopharma Inc : On Sept 2, co entered into note purchase agreement - SEC filing . Notes bear interest at rate of 5 percent per annum . Co issued to Redmile subordinated convertible promissory notes (in aggregate original principal amount of $10 million Source: (http://bit.ly/2c1a5cZ) Further company coverage: [ARRY.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Array Biopharma announces FDA acceptance of Binimetinib for patients with advanced NRAS-mutant melanoma
Thursday, 1 Sep 2016 08:00am EDT 

Array Biopharma Inc : Announces FDA acceptance Of Binimetinib NDA for patients with advanced NRAS mutant melanoma . Says currently preparing for an application orientation meeting (AOM) with FDA in September 2016 .FDA set target action date under prescription drug user fee act (PDUFA) of June 30, 2017.  Full Article

Array Biopharma files for mixed shelf of up to $300 mln
Thursday, 18 Aug 2016 05:24pm EDT 

Array Biopharma Inc :Files for mixed shelf of up to $300 million - SEC filing.  Full Article

Array Biopharma Q4 net loss $0.17 per share
Thursday, 4 Aug 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2016 . Net loss for Q4 was $0.17 per share . Revenue for Q4 of fiscal 2016 was $43.2 million, compared to $43.0 million for prior sequential quarter .Q4 earnings per share view $-0.14, revenue view $41.5 million -- Thomson Reuters I/B/E/S.  Full Article

Array Biopharma names new CFO
Thursday, 28 Jul 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma announces appointment of Jason Haddock as chief financial officer .Haddock's appointment effective today and he will be replacing David Horin, who had been acting as Array's interim CFO.  Full Article

Array biopharma submits Binimetinib new drug application to U.S. FDA
Thursday, 30 Jun 2016 04:00pm EDT 

Array Biopharma Inc : Array biopharma submits binimetinib new drug application to u.s. Fda . Binimetinib was generally well-tolerated and adverse events reported were consistent with previous results . There was no statistically significant difference demonstrated in overall survival,median overall survival favored binimetinib arm .Array biopharma submits binimetinib new drug application to u.s. Fda.  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

Array BioPharma appoints patricia henahan as chief financial officer
Tuesday, 8 Sep 2015 08:00am EDT 

Array BioPharma:Names patricia henahan as chief financial officer.  Full Article

Array BioPharma enters into asset purchase agreement with Accuratus Lab Services Inc - Form 8-K
Tuesday, 2 Jun 2015 08:01am EDT 

Array BioPharma:Says on June 1 Array BioPharma entered into an Asset Purchase Agreement with Accuratus Lab Services, Inc.Pursuant to which Accuratus acquired certain assets and assumed certain liabilities relating to Array’s chemistry, manufacturing and controls business in a transaction that closed on June 1.Says the sale of the CMC business provides this world-class team the opportunity to grow and achieve continued success, while continuing to provide expert support to Array’s drug discovery and development programs.Transaction included the transfer of equipment, inventory and third party contracts of Array relating to its CMC business as well as Array’s facilities lease in Longmont, Colorado and the retention of approximately 33 Array CMC employees by Accuratus following the closing.Accuratus paid Array a cash purchase price at closing for the CMC assets, and Array is entitled to receive additional consideration for the CMC assets contingent upon achievement of revenue targets for the CMC business during the first and second year following the closing.  Full Article

BRIEF-Array Biopharma prices public offering at $6.25 per share

* Array Biopharma announces pricing of public offering of common stock